The Japan Times said that a group of scientists from the “Tokyo Institute of Medical Sciences” is designing a vaccine against the Corona virus that can protect humans from this virus for life.
According to the newspaper, clinical trials of the drug may begin in 2023.
The group, led by Professor Mitenori Kohara, has adopted the smallpox vaccine designed by the 18th century British physician Edward Jenner as the basis for its work.
The idea of the Japanese scientists is to obtain a recombinant smallpox virus vaccine that contains the spike protein of the SARS-CoV-2 virus that causes Covid-19 disease.
According to them, this approach could lead to the development of lifelong cellular immunity against the Corona virus.
Experiments in mice using the recombinant vaccine virus that encodes the bird flu gene showed high levels of antibodies lasting for more than 20 months. During that, all the mice that were vaccinated with the vaccine survived, and then transmitted bird flu infection to them after 20 months.
For his part, Professor Kohara told the newspaper: “I have tested different vaccine technologies, including adenovirus and RNA vaccines, but the recombinant smallpox vaccine has proven to be the most powerful among them.”
According to him, the side effects of this vaccine are few and it does not require special transportation and storage facilities. It is reported that the Japanese pharmaceutical company, Nobelpharma, intends to implement the first and second phases of clinical trials for the Kohara vaccine, in the first half of 2023.